Health, Longevity & Biohacking
New CTEP Inhibitor Drug Improves Alzheimer's Biomarkers by Rescuing Dysfunctional Brain HDL
Peter Attia Drive
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.
"In that Broadway trial where you administered obesetrapib, they actually looked at some of the biomarkers of Alzheimer's disease. The phosphorylated P-tau, the amyloid 40/42 ratio. And they saw some very interesting movement in the right direction of those Alzheimer's-associated biomarkers."
Dayspring revealed that obesetrapib, a new cholesterol ester transfer protein inhibitor, improved Alzheimer's biomarkers in the BROADWAY trial. The drug increases ApoA-1 production, which can cross into the brain and potentially rescue dysfunctional ApoE4 lipoproteins. The pharmaceutical company is now funding cognitive function trials based on these promising biomarker results.
From this episode
Peter Attia Drive